These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 7624358)

  • 1. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.
    Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.
    Jacks T; Hickey G; Judith F; Taylor J; Chen H; Krupa D; Feeney W; Schoen W; Ok D; Fisher M
    J Endocrinol; 1994 Nov; 143(2):399-406. PubMed ID: 7830002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
    Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles.
    Hickey G; Jacks T; Judith F; Taylor J; Schoen WR; Krupa D; Cunningham P; Clark J; Smith RG
    Endocrinology; 1994 Feb; 134(2):695-701. PubMed ID: 8299565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
    Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS
    Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue.
    Cheng K; Chan WW; Butler B; Wei L; Schoen WR; Wyvratt MJ; Fisher MH; Smith RG
    Endocrinology; 1993 Jun; 132(6):2729-31. PubMed ID: 8389289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary and extrapituitary action sites of the novel nonpeptidyl growth hormone (GH) secretagogue L-692,429 in the chicken.
    Geris KL; Hickey GJ; Berghman LR; Visser TJ; Kühn ER; Darras VM
    Gen Comp Endocrinol; 1998 Aug; 111(2):186-96. PubMed ID: 9679090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistent GH responses to repeated injection of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585.
    Fairhall KM; Mynett A; Smith RG; Robinson IC
    J Endocrinol; 1995 Jun; 145(3):417-26. PubMed ID: 7636426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel non-peptidyl growth hormone secretagogue.
    Cheng K; Chan WW; Butler B; Wei L; Smith RG
    Horm Res; 1993; 40(1-3):109-15. PubMed ID: 7905455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
    Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
    Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent, orally bioavailable benzazepinone growth hormone secretagogue.
    DeVita RJ; Bochis R; Frontier AJ; Kotliar A; Fisher MH; Schoen WR; Wyvratt MJ; Cheng K; Chan WW; Butler B; Jacks TM; Hickey GJ; Schleim KD; Leung K; Chen Z; Chiu SL; Feeney WP; Cunningham PK; Smith RG
    J Med Chem; 1998 May; 41(10):1716-28. PubMed ID: 9572898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues.
    Barakat KJ; Cheng K; Chan WW; Butler BS; Jacks TM; Schleim KD; Hora DF; Hickey GJ; Smith RG; Patchett AA; Nargund RP
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1431-6. PubMed ID: 9871779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
    Doi N; Hirotani C; Ukai K; Shimada O; Okuno T; Kurasaki S; Kiyofuji T; Ikegami R; Futamata M; Nakagawa T; Ase K; Chihara K
    Arzneimittelforschung; 2004; 54(12):857-67. PubMed ID: 15646370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
    Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonpeptidyl growth hormone secretagogue.
    Smith RG; Cheng K; Schoen WR; Pong SS; Hickey G; Jacks T; Butler B; Chan WW; Chaung LY; Judith F
    Science; 1993 Jun; 260(5114):1640-3. PubMed ID: 8503009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of L-692,429-stimulated rat growth hormone release by a weak substance P antagonist: L-756,867.
    Cheng K; Wei L; Chaung LY; Chan WW; Butler B; Smith RG
    J Endocrinol; 1997 Jan; 152(1):155-8. PubMed ID: 9014851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
    Gertz BJ; Barrett JS; Eisenhandler R; Krupa DA; Wittreich JM; Seibold JR; Schneider SH
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1393-7. PubMed ID: 8077339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic central infusion of growth hormone secretagogues: effects on fos expression and peptide gene expression in the rat arcuate nucleus.
    Bailey AR; Giles M; Brown CH; Bull PM; Macdonald LP; Smith LC; Smith RG; Leng G; Dickson SL
    Neuroendocrinology; 1999 Aug; 70(2):83-92. PubMed ID: 10461022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.